The Affiliated Brain Hospital of Guangzhou Medical University
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
li, xuan j
NCT06259526: A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression

Recruiting
2
260
RoW
Placebo group, JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules, JS1-1-01 low-dose group, JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules, JS1-1-01 pills; JS1-1-01 placebo pills, JS1-1-01 high-dose group, JS1-1-01 pills; Duloxetine hydrochloride placebo capsules, Active drug group, JS1-1-01 placebo pills; Duloxetine hydrochloride enteric coated capsule
Tasly Pharmaceutical Group Co., Ltd
Depression
04/25
04/25
GENIUS, NCT04849325: IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease

Recruiting
N/A
120
RoW
Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titanâ„¢), Percutaneous Transluminal Angioplasty (PTA) Device
Biotyx Medical (Shenzhen) Co., Ltd.
Critical Limb Ischemia (CLI)
04/24
10/24
Ning, Yuping
NCT05181475: Long-term Efficacy and Safety Study of GV-971

Active, not recruiting
4
800
RoW
Sodium Oligomannate Capsules (GV-971)
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Alzheimer Disease
01/25
06/25
NCT05908695: An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

Recruiting
4
1312
RoW
GV-971, Placebo
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Alzheimer's Disease
06/29
12/29
NCT04825860: A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

Terminated
2/3
83
Japan, RoW
SEP-363856 50 mg, SEP-363856 75 mg, Placebo
Sumitomo Pharma Co., Ltd.
Schizophrenia
10/23
10/23
Fukasawa, Takashi
NCT04825860: A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

Terminated
2/3
83
Japan, RoW
SEP-363856 50 mg, SEP-363856 75 mg, Placebo
Sumitomo Pharma Co., Ltd.
Schizophrenia
10/23
10/23
Zhou, Yanling
No trials found

Download Options